- Published: Friday, 23 April 2021 09:30
By Dr. Jim Halverson
On April 13, the Centers for Disease Control and Food and Drug Administration recommended a pause in the use of Johnson & Johnson/Janssen COVID-19 vaccine.
Of the nearly 7 million doses administered in the United States since the FDA’s Emergency Use Authorization Feb. 27, six cases of a rare and severe type of blood-clotting disorder have been reported in people after receiving the J&J/Janssen COVID-19 vaccine.
All reports occurred among women between the ages of 18 and 48, and symptoms occurred six to 13 days after vaccination. As of April 13, of the more than 180 million doses administered so far of the Pfizer-BioNTech or Moderna vaccines, no reports matching those of the J&J/Janssen vaccine had been received.
The CDC and FDA recommended this pause to communicate with and prepare the healthcare system to recognize this potential severe …